Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection.
Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection.
复制标题
大剂量静脉注射免疫球蛋白治疗继发登革热病毒感染的严重血小板减少症缺乏疗效。
DOI：
--
复制
发表时间：
2007
影响因子：
3.3
通讯作者：
K. Oishi
中科院分区：
文献类型：
--
作者：
E. Dimaano;M. Saito;S. Honda;E. Miranda;M. T. Alonzo;Myra D. Valerio;C. Mapua;S. Inoue;Atsushi Kumaori;R. Matias;F. Natividad;K. Oishi
由于大多数继发性登革热病毒感染病例与血小板相关 IgG 水平升高有关，因此高剂量静脉注射免疫球蛋白 (IVIG) 可能会对该疾病中严重血小板减少症的发展产生影响。一项随机对照研究进行了两个治疗组，包括治疗（IVIG）组（n = 15）和非治疗（非 IVIG）组（n = 16），以确定高剂量的 IVIG 是否能有效加速继发性登革热病毒感染患者的血小板减少症恢复。两组之间的基线人口统计数据没有发现显着差异。没有观察到 IVIG 的副作用，但在继发性登革热感染患者中没有发现加速血小板计数恢复的作用。 IVIG 缺乏疗效表明巨噬细胞通过 Fc γ 受体清除血小板并不是这种疾病的主要机制。
Because most cases of secondary dengue virus infection are associated with an increased level of platelet-associated IgG, a high dose of intravenous immunoglobulin (IVIG) may have an effect on the development of severe thrombocytopenia in this disease. A randomized, controlled study was conducted with two treatment groups consisting of a treatment (IVIG) group (n = 15) and a non-treatment (non-IVIG) group (n = 16) to determine whether a high dose of IVIG is effective in hastening the recovery from thrombocytopenia in patients with secondary dengue virus infection. No significant difference was found in the baseline demographic data between the two groups. No adverse effect of IVIG was observed, but no effect in hastening the recovery of platelet counts was found in patients with secondary dengue infections. The lack of efficacy of IVIG suggests that platelet clearance by macrophages through Fc gamma receptors is not a primary mechanism in this disease.